Publication | Open Access
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
26
Citations
31
References
2022
Year
ClinicalTrials.gov, NCT02856425 . Registered August 4, 2016 - Prospectively registered.
| Year | Citations | |
|---|---|---|
Page 1
Page 1